Data compiled by Redley Lamar · ChainSifter Intelligence
5Suppliers
5Customers
2Debt Items
15Related Chains
Source-Backed Evidence Depth
Biohaven Ltd. (BHVN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
13Total relationships
1Distinct source URLs
7High confidence
0.755Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Biohaven Ltd. Suppliers
Ticker
Name
Confidence
Evidence
BIOHAVEN-BIOSCIENCES-IRELAND-LIMITED
BIOHAVEN-BIOSCIENCES-IRELAND-LIMITED
90%
We have historically outsourced all of the research and clinical development for our programs under a master services agreement with our subsidiaries, Biohaven Pharmaceuticals, Inc. ("BPI") and Bioha…
BIOHAVEN-PHARMACEUTICALS-INC
BIOHAVEN-PHARMACEUTICALS-INC
90%
We have historically outsourced all of the research and clinical development for our programs under a master services agreement with our subsidiaries, Biohaven Pharmaceuticals, Inc. ("BPI") and Bioha…
CONTRACT-MANUFACTURING-ORGANIZATIONS
CONTRACT-MANUFACTURING-ORGANIZATIONS
80%
The Company has entered into agreements with several contract manufacturing organizations ("CMOs") and contract research organizations ("CROs") to provide products and services in connection with the…
CONTRACT-RESEARCH-ORGANIZATIONS
CONTRACT-RESEARCH-ORGANIZATIONS
80%
The Company has entered into agreements with several contract manufacturing organizations ("CMOs") and contract research organizations ("CROs") to provide products and services in connection with the…
Reciprocal relationship from ZBIO graph: Reciprocal relationship from BHVN graph: Reciprocal relationship from ZBIO graph: nt in the US, including the following Phase 3 programs: zasocitinib, a perip…
Biohaven Ltd. Customers
Ticker
Name
Confidence
Evidence
BIOHAVEN-BIOSCIENCES-IRELAND-LIMITED
BIOHAVEN-BIOSCIENCES-IRELAND-LIMITED
62%
bo-controlled study evaluating two dosing schedules of taldefgrobep versus placebo. Approximately 150 participants will be randomized to receive taldefgrobep or matching placebo over a 24-week double…
BIOHAVEN-PHARMACEUTICAL-HOLDING-COMPANY-LTD
BIOHAVEN-PHARMACEUTICAL-HOLDING-COMPANY-LTD
62%
acellular Proteins (“MoDE”) and Targeted Removal of Aberrant Protein ("TRAP") extracellular protein degradation for immunological diseases; and myostatin-activin pathway targeting agent for neuromusc…
BIOHAVEN-PHARMACEUTICALS-INC
BIOHAVEN-PHARMACEUTICALS-INC
62%
bo-controlled study evaluating two dosing schedules of taldefgrobep versus placebo. Approximately 150 participants will be randomized to receive taldefgrobep or matching placebo over a 24-week double…
MODA-PHARMACEUTICALS-LLC
MODA-PHARMACEUTICALS-LLC
62%
at a purchase price per share of $ 67.98 , subject to certain specified development milestones and the Company achieving a specified market capitalization. The Warrant was recorded at its initial fai…
PYRAMID-BIOSCIENCES-INC
PYRAMID-BIOSCIENCES-INC
62%
at a purchase price per share of $ 67.98 , subject to certain specified development milestones and the Company achieving a specified market capitalization. The Warrant was recorded at its initial fai…
Biohaven Ltd. Debt Obligations
Instrument
Description
Confidence
Evidence
BHVN-DEBT
Debt stack $286.2M
90%
Market cache reports total debt of $286.2M.
BHVN-DEBT-8186
Warrants outstanding: 3340000
90%
xbrl warrant detail from xbrl 2024-12-31.
Biohaven Ltd. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Biohaven Ltd..
Biohaven Ltd. Ownership
Holder
Name
Confidence
Evidence
BHVN-OWNER-JANUS-HENDERSON-GROUP-PLC
JANUS HENDERSON GROUP PLC
90%
13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 278 tracked holders.
